Celonis Opens New Offices in Denmark and Sweden to Accelerate Value Creation through Process Mining for Customers in the Nordics
23.8.2023 11:00:00 EEST | Business Wire | Press release
Celonis, the global leader in Process Mining, today announced the opening of its new offices in Copenhagen, Denmark and Stockholm, Sweden. The launch of these new sites bolsters Celonis’ existing operations and adoption for its market leading process mining technology in the Nordics.
Celonis’ investment in the region is a reflection of the enormous demand for value creating technologies from Nordics’ businesses, especially in the areas of manufacturing and IT both of which have already greatly benefited from process mining.
Since starting operations in the Nordics about three years ago, Celonis has grown to more than 40 employees and more than 70 customers, including some of the most innovative and well-known companies in the Nordics such as Nokia, Telia and Equinor.
The opening of the new Swedish office overlooking Norrmalmstorg will be honored with a ribbon-cutting ceremony and a cocktail reception for prospects, partners and customers. Bastian Nominacher, co-CEO and co-founder of Celonis, will be in attendance to deliver a speech.
“The new Stockholm and Copenhagen offices are important steps in our mission to bring the value of process mining to customers across all regions and industries,” said Nominacher. “Our strengthened presence in the Nordics enables us to accelerate process mining adoption for enterprises in the Nordics. We look forward to helping organizations in the region yield immediate cash impact and radically improve customer experience. Furthermore, the Nordic countries have a strong focus on environmentalism and sustainability, and Celonis has a proven track record of helping customers reduce carbon emissions. We will leverage our process mining technology, to enable customers in the region to perform at levels they never thought possible.”
“These new office locations are a clear commitment to Celonis’ expansion in the Nordics,” said Michael Zink, Regional Vice President and General Manager of the Nordics at Celonis. “This region has many companies focused on driving innovation, with a well-educated and skilled workforce. Ingenuity and sustainability also go hand in hand in the Nordics. Our market leading process mining technology will accelerate business performance for companies in the region, delivering fast and sustainable value that support the innovation and sustainability ethos found throughout organizations here in the Nordics.”
Mikael Schwarzman, Sales Director & Country Leader at Celonis, has been named Site Leader in the Stockholm office and will oversee operations across Sweden. Sales Director Karsten Mayland is Site Leader for the Copenhagen office.
This office opening follows Celonis being named leader of the first-ever 2023 Gartner® Magic Quadrant™ for Process Mining Tools, as well as leader in the Everest Group PEAK Matrix® for Process Mining for the fourth year in a row.
About Celonis
Celonis enables customers to optimize their business processes. Powered by its leading process mining technology, Celonis provides a unique set of capabilities for business executives and users to continuously find improvement opportunities within and across processes, and execute targeted actions to rapidly enhance process performance. This optimization yields immediate cash impact, radically improves customer experience, and reduces carbon emissions. Celonis has thousands of implementations with global customers and is headquartered in Munich, Germany and New York City, USA with more than 20 offices worldwide.
© 2023 Celonis SE. All rights reserved. Celonis, Execution Management System, EMS, Process Sphere and the Celonis “droplet” logo are trademarks or registered trademarks of Celonis SE in Germany and other jurisdictions. All other product and company names are trademarks or registered trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230823526175/en/
Contact information
Celonis
press@celonis.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom